FDA Brief

Warning letters Animal

FDA warning letter to

Boehringer Ingelheim Animal Health USA

High riskIssued Mar 1, 2024Posted Mar 12, 2024Center for Veterinary Medicine

FDA warned Boehringer Ingelheim Animal Health USA that Senvelgo promotional materials falsely claimed safety and effectiveness in previously insulin-treated cats.

What happened

FDA reviewed Boehringer Ingelheim's promotional communications for Senvelgo, including a Vet Detailer on the Senvelgo website accessed March 1, 2024. FDA found the materials made false or misleading claims about safety and effectiveness, including saying Senvelgo was shown safe and effective in cats previously treated with insulin. FDA said this conflicts with the approved labeling, whose strongest safety warning and do-not-use section say not to use Senvelgo in cats previously treated with insulin.

What FDA found

  1. The Vet Detailer said Senvelgo had demonstrated excellent efficacy and safety in trials that included previously insulin-treated cats.

    FD&C Act section 502(a) [21 U.S.C. 352(a)]; section 502(n) [21 U.S.C. 352(n)]
  2. That claim conflicted with the approved labeling, which has a strong safety warning and do-not-use statement for cats previously treated with insulin.

    FD&C Act section 201(n) [21 U.S.C. 321(n)]; 21 CFR 202.1(e)(5)
  3. The promotion left out that 12 of 38 previously insulin-treated cats (32%) developed ketones in urine or ketoacidosis (a dangerous acid buildup in the blood) during the first week and were removed from the study.

    FD&C Act section 201(n) [21 U.S.C. 321(n)]; 21 CFR 202.1(e)(5)
  4. The Vet Detailer claimed cats on Senvelgo had fewer monitoring requirements and less-intensive monitoring than cats on traditional insulin treatment without saying this applied only after stabilization.

    FD&C Act section 502(a), (n); section 201(n); 21 CFR 202.1(e)(5)
  5. FDA said the promotional communication misbranded Senvelgo—made it falsely labeled—so its distribution was illegal.

    FD&C Act section 301(a) [21 U.S.C. 331(a)]

What FDA wants

FDA asks the company to stop violations and, within 15 working days of receipt, submit a written response listing all Senvelgo promotional communications with such representations and explaining plans to discontinue them or cease distribution. If it cannot complete the actions, it must state why and when it will.

Who should pay attention

  • veterinarians prescribing diabetes treatments for cats
  • animal health companies promoting veterinary drugs
  • regulatory affairs teams reviewing veterinary promotional materials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. HydraMed IV LLC dba HydraMed

    FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Eden Health International Inc. dba Eden

    FDA warned Eden Health International that its telehealth website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Trinity HealthCare Supply, LLC dba altRx

    FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.

    Low
  4. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium